1[1]Motoji T, Motomura S, Wang YH. Multidrug resistance of acute leukemia and a strategy to overcome it [J].Int J Hematol,2000,72(4):418-424.
2[2]Burg D,Filippov DV,Hermanns R,et al. Peptidomimetic glutathione analogues as novel gammaGT stable GST inhititors[J].Bio Med Chem,2002,10(1):195-205.
3[3]Mistry P, Stewart AJ,Dangerfield W,et al. In vitro and vivo characterization of XR11576,a novel,orally active,dual inhibitor of topoisomerase Ⅰ and Ⅱ [J].Anticancer Drugs,2002,13(1): 15 -28.
4[4]Swannie HC,Kaye SB.Protein kinase C inhibitors[J].Curr Oncol Rep,2002,4(1):37-46.
5[5]Hannun YA.Apoptosis and the dilemma of cancer chemotherapy[J].Blood,2001,89(6):1845-1853.
6[6]Thomas A,Reed JC.Drug induced apoptosis in B-cell chronic lymphocytic leukemia:relationship between p53gene mutation and BCL-2/Bax protein in drug resistance [J].Oncogene,2001,12:1055-1062.
7[7]Wang J,LenardoM.Roles of caspases in apoptosis,development,and cytokine maturation revealed by homozygous gene deficiencies[J].J Cell Sci,2000,113:753-757.
8[8]Kobayashi H,Takemura Y,Miyachi H.Novel approaches to reversing anti-cancer drug resistance using gene-specific therapeutics[J].Hum Cell,2001,14(3): 172-184.
9[9]Kigawa J,Sato S,Shimada M,et al.p53 gene status and chemosensitivity in ovarian cancer [J].Hum Cell,2001,14(3):165-171.
10[10]Funato T,Kozawa K,Kaku M,et al. Modification of the sensitivity to cisplatin with c-myc over-expression or downregulation in colon cancer cells[J].Anticancer Drugs,2001,10(10):829-834.
2Di Leo A,Isola J,Piette F. A meta-analysis of phase Ⅲ trials evaluating the predictive value of HER-2 and topoisomerase Ⅱ alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy[J].CANCER RESEARCH,2009,(12):705.
3O'Malley FP,Chia S,Tu D. Topoisomerase Ⅱ alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial[J].Breast Cancer Research and Treatment,2011,(02):401-409.
4Jacquemier J,Penault-Llorca F,Mnif H. Identification of a basal-like subtype and comparative effect of epirubicinbased chemotherapy and sequential epirubicin followed by docetaxel chemotherapy in the PACS 01 breast cancer trial:33markers studied on tissue-microarrays(TMA)[J].Journal of Clinical Oncology,2006,(03):509.
